Insmed (INSM) Net Cash Flow Growth (5y) (2015 - 2026)
Insmed (INSM) Net Cash Flow Growth (5y) (2015 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,912.79 Bn | 1,912.72 Bn | - |
| 3 | Akari Therapeutics | 1,045.06 Bn | 1,045.06 Bn | - |
| 4 | BeOne Medicines | 470.64 Bn | 465.84 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.91 Bn | 115.67 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.07 Bn | 61.31 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.77 Bn | 62.77 Bn | - |
| 8 | Argenx Se | 56.21 Bn | 51.02 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.60 Bn | 37.60 Bn | - |
| 10 | Insmed | 22.95 Bn | 21.73 Bn | 258.54 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 20.96% |
| Dec 31, 2025 | 38.63% |
| Sep 30, 2025 | -77.85% |
| Jun 30, 2025 | 32.82% |
| Mar 31, 2025 | -21.16% |
| Dec 31, 2024 | 31.77% |
| Sep 30, 2024 | -64.37% |
| Jun 30, 2024 | 29.21% |
| Mar 31, 2024 | 28.68% |
| Dec 31, 2023 | 39.76% |
| Sep 30, 2023 | -13.90% |
| Jun 30, 2023 | -46.52% |
| Mar 31, 2023 | -18.58% |
| Dec 31, 2022 | 72.67% |
| Sep 30, 2022 | -14.98% |
| Jun 30, 2022 | -23.22% |
| Mar 31, 2022 | -40.34% |
| Dec 31, 2021 | -27.90% |
| Sep 30, 2021 | -29.20% |
| Jun 30, 2021 | 81.04% |